Klaus Edvardsen, MD, PhD

Chief Development Officer

Dr. Edvardsen joins CureVac from Merck KGaA, where he led early- and late-stage global oncology development as a Senior Vice President and Head of Global Oncology Development. He served at AstraZeneca prior to that, as Senior Vice President and Head of Global Medicines Development Oncology, where he was responsible for the overall development strategy for oncology and hematology programs. Dr. Edvardsen also held leadership roles at both GlaxoSmithKline PLC and at Genmab A/S in medicines development within various therapeutic areas.

Dr. Edvardsen’s previous research work includes several positions as adjunct member and professor in oncology at various institutes in Denmark, USA, Norway and Sweden. Dr. Edvardsen holds a MD degree as well as a PhD in cancer biology from University of Copenhagen.

Back to Executive Board